Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

Rheumatoid Arthritis Clinical Trial

Official title:

A Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue From Subjects Clinically Diagnosed With Rheumatoid Arthritis (RA)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04078191
• Other study ID #: NAV3-32
• Secondary ID: 2018-003418-41
• Status: Recruiting
• Phase: Phase 2
• Start date: September 14, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: April 2024
• Source: Navidea Biopharmaceuticals
• Contact: Michael Blue
• Phone: 614-973-7555
• Email: mblue[@]navidea.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a comparison of quantitative Tc 99m tilmanocept imaging with IHC analysis of CD206 expression in synovial tissue of RA subjects.

Description:

This is a Manocept Platform phase 2b, open-label, multi-center, multinational, non-randomized, single-dose study designed to assess the relationship between quantitative Tc 99m tilmanocept planar imaging and synovial histopathology in subjects clinically diagnosed with RA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.

2. Women and men of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) for the duration of the study.

3. The subject is at least 18 years of age and was = 18 years of age at the time of RA diagnosis.

4. The subject has RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of = 6/10 at or before screening).

5. The subject has a 28-joint disease activity score (DAS28) of = 3.2 (includes the C-reactive protein [CRP] test and visual analog scale [VAS]).

6. Subjects receiving traditional DMARDs must have been on therapy for = 90 days and at a stable dose for = 30 days prior to the first imaging visit (Day 0).

7. If the subject is receiving biologic disease-modifying antirheumatic drug (bDMARD) or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 180 days prior to the first imaging visit (Day 0).

8. If the subject is receiving NSAIDs (nonsteroidal anti-inflammatory drug) or oral corticosteroids, the dose has been at a stable dose for = 28 days prior to imaging. The corticosteroid dose should be = 10 mg/day of prednisone or an equivalent steroid dose.

9. The subject has a hand or wrist joint with a minimum ultrasound gray-scale synovitis score of 2 (range 0 to 3).

Exclusion Criteria:

1. The subject is pregnant or lactating.

2. The subject size or weight is not compatible with imaging per the investigator.

3. The subject has had or is currently receiving radiation therapy or chemotherapy.

4. The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.

5. The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 3 times the upper limit of normal.

6. The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation.

7. The subject has a known allergy to or has had an adverse reaction to dextran exposure.

8. The subject has received an investigational product within 30 days prior to the Tc 99m tilmanocept administration (Day 0).

9. The subject has received intra-articular corticosteroids = 8 weeks prior to imaging (Day 0).

10. The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to the administration of Tc 99m tilmanocept (Day 0).

11. The subject has an intolerance to anesthetic and antiseptic agents indicated for the synovial biopsy procedure.

12. The subject is currently receiving anticoagulants (oral anti-platelet agents are permitted) or has a condition that is contraindicated with ultrasound-guided synovial biopsy e.g., needle phobia.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Tc 99m tilmanocept
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Locations

Country	Name	City	State
United Kingdom	Barts Health	London
United Kingdom	Royal Free Hospital	London
United States	Northwestern University	Chicago	Illinois
United States	Attune Health	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Navidea Biopharmaceuticals

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between joint-specific tilmanocept uptake and CD206 expression	The correlation between joint-specific tilmanocept uptake value (TUVjoint) and the number and area fraction of CD206 expression as determined by IHC assessment.	Through study completion, up to 45 days
Secondary	Correlation between joint-specific tilmanocept uptake and CD68 and CD163 expression	The correlation between TUVjoint and the number and area fraction of CD68 and CD163 determined by IHC assessments.	Through study completion, up to 45 days
Secondary	Classification of synovial anatomic pathotype by IHC assessment	Classification of synovial anatomic pathology into; Lympho-myeloid; Diffuse myeloid; Pauci-immune fibroid types as a function of CD68, CD163, CD206, CD3, CD20, CD55, and TE7 expression determined by IHC assessments using a polytomous logistic regression model.	Through study completion, up to 45 days
Secondary	Correlation between CD206, CD68, and CD163 expression	The correlation between the expression of CD68, CD163, and CD206.	Through study completion, up to 45 days